She has been on the floor for three nights. She came in through the emergency room from her primary-care office with hemoglobin in the seven range and a story of heavy menstrual bleeding that had, over six weeks, escalated from heavier-than-usual to soaking-through-pads-every-hour. We have transfused two units. We have run her on intravenous conjugated equine estrogen at high dose for thirty-six hours with a partial response — the bleeding slowed but did not stop, the hemoglobin stabilized but did not climb. We have added tranexamic acid by mouth, three times a day. She has been examined twice, the last time this morning, and there are large clots in the vault but no active bleeding now. The surgical backup — a dilation and curettage with an intrauterine Foley balloon for tamponade — has been on the operating room's add-on list for two days as a contingency. We have not needed it.
She is being discharged this afternoon. Her partner is coming to pick her up. She is asking, reasonably, how she keeps this from happening again. The plan I am about to give her is the standard plan: a combined oral contraceptive at a tapering dose for three weeks, with a planned withdrawal bleed afterward, and a follow-up appointment in two weeks for a hemoglobin check and a contraception conversation.
This is the operational reality of outpatient gynecology in 2026: the prescription I write at discharge is not, in the strict operational sense, a prescription. It is a request. The request is filled — or not filled, or filled with a substituted product, or delayed for twenty-four hours under a pharmacist-counseling protocol, or refused outright — by the chain-pharmacy system that has, in the post-Dobbs environment, made stocking and dispensing decisions whose internal logic is not the standard of care but the chain's corporate legal exposure.
The oral contraceptive taper I am about to prescribe is, on its face, the textbook treatment for an episode of acute anovulatory bleeding in a hemodynamically stable patient with a normal endometrial biopsy. The medication is generic. The cost is, with insurance, a copay; without insurance, ten to twenty dollars per cycle at a chain pharmacy. The clinical indication — heavy menstrual bleeding suppression after acute bleeding — is documented in the chart, in the discharge summary, and in the prescription itself. The mechanism of action is well-established. The dispensing should be unremarkable.
In 2026, the dispensing is not always unremarkable. Several of the four major chains have implemented pharmacist-counseling requirements before dispensing hormonal contraception — requirements that, in operational practice, produce delays of two to twenty-four hours between the patient presenting with a valid prescription and the patient leaving with the medication. Some chains have, in some states, declined to stock the specific formulation I am about to prescribe, defaulting the patient to a substitution that is either clinically inferior or simply not what I wrote. Several chains have rolled the contraceptive-dispensing decision into a broader post-Dobbs legal-counsel framework whose operational effect, on the ground, is that the patient driving home from her three-night admission for severe anemia from acute uterine bleeding may or may not be able to fill the prescription that prevents the next episode.
The intravenous estrogen we ran her on in-hospital is a generic-injectable product whose national supply is concentrated among a small number of manufacturers and has been on intermittent shortage every year since 2021. The tranexamic acid we added is a generic whose pharmacy stocking decisions are similarly chain-dependent. The conjugated estrogen for her post-discharge taper — if I wrote it instead of the OCP — would be a Premarin product whose chain-pharmacy availability has been unpredictable in this catchment area for eighteen months. The clinical plan that ends in a discharge prescription is, increasingly, a plan whose final execution depends on a logistics system the clinician does not control and that the patient cannot, from the discharge bed, evaluate.
What I can do, at discharge, is the writing of the prescription, the explanation of the regimen, the follow-up appointment, and one phone call I make most discharges now to the chain pharmacy closest to the patient's home to confirm that the medication is in stock and to ask whether the chain's counseling requirements will produce a same-day fill. The phone call adds four to twelve minutes to the discharge. The phone call is not in the workflow. The phone call is what I do because the workflow, in 2026, presumes a pharmacy backstop that does not, in operational practice, reliably exist.
I have her give me the name of her pharmacy. I make the call. The pharmacist on the line tells me that the medication is in stock, that the chain has no specific counseling delay on this formulation in this state, and that the patient can come in this afternoon and receive the medication today. I write the prescription. I send it electronically. I tell the patient what the pharmacist told me. She nods. She and her partner leave.
What I do not do, at this discharge, is the work that the next discharge after hers will require — the same phone call to a different chain in a different state with a different counseling protocol in a different post-Dobbs legal exposure, repeated across the discharges I will do this week, every week, until the federal-and-state regulatory environment that produced this operational reality is restructured. The phone call is the workaround. The workaround is what clinicians do when the system stops doing the thing the system was built to do. When the medicine has limits, the care does not. The care, this week, was the phone call.
DICT-00001 (de-identified).